García Silva, SusanaBenito Martín, AlbertoSánchez Redondo, SaraHernández Barranco, AlbertoXiménez Embún, PilarNogues Vera, LauraMazariegos, Marina S.Brinkmann, KayAmor López, AnaMeyer, LisaRodríguez, CarlosGarcía Martín, CarmenBoskovic, JasminkaLetón, RocíoMontero, CristinaRobledo, MercedesSantambrogio, LauraSue Brady, MarySzumera Ciećkiewicz, AnnaKalinowska, IwonaSkog, JohanNoerholm, MikkelMuñoz, JavierOrtiz Romero, Pablo LuisRuano, YolandaRodríguez Peralto, José LuisRutkowski, PiotrPeinado, Héctor2026-01-272026-01-272019-04-11García-Silva S, Benito-Martín A, Sánchez-Redondo S, Hernández-Barranco A, Ximénez-Embún P, Nogués L, et al. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF V600E mutation. Journal of Experimental Medicine 2019;216:1061–70. https://doi.org/10.1084/jem.20181522.0022-10071540-953810.1084/jem.20181522https://hdl.handle.net/20.500.14352/131088Liquid biopsies from cancer patients have the potential to improve diagnosis and prognosis. The assessment of surrogate markers of tumor progression in circulating extracellular vesicles could be a powerful non-invasive approach in this setting.We have characterized extracellular vesicles purified from the lymphatic drainage also known as exudative seroma (ES) of stage III melanoma patients obtained after lymphadenectomy. Proteomic analysis showed that seroma-derived exosomes are enriched in proteins resembling melanoma progression. In addition, we found that the BRAFV600E mutation can be detected in ES-derived extracellular vesicles and its detection correlated with patients at risk of relapse.engjournal articlehttps://doi.org/10.1084/JEM.20181522https://rupress.org/jem/article/216/5/1061/121010/Use-of-extracellular-vesicles-from-lymphaticrestricted accessHuman disease geneticsSolid tumorsOncologíaDermatología3201.06 Dermatología3207.13 Oncología